Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-624 in Major Depressive Disorder
NCT04479852Phase 2Completed
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of forvisirvat in major depressive disorder (MDD), sponsored by Sirtsei Pharmaceuticals, Inc.. Started Sep 2020; status: completed.
02
Drugs
forvisirvat
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04479852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479852.